U.S. FDA approves once-daily Viramune® XR™ tablet for use in combination with other antiretroviral agents for treatment of HIV-1 infection in adults

Ingelheim, Germany, 31 March 2011 - Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved Viramune® XR™ (nevirapine) extended-release tablets — a one-pill, once-daily (400 mg) formulation of nevirapine — for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

“With the approval of once-daily Viramune® XR™, patients in the U.S.A. now have the benefit of a new HIV treatment option for use in combination with their other HIV medications,” said Joseph Gathe, Jr., M.D., clinical instructor, Department of Internal Medicine, Baylor College of Medicine and lead investigator of the VERxVE clinical trial. “Physicians in the U.S.A. can now switch their current Viramune® patients to a once-daily product with demonstrated comparable safety and efficacy.”